Cargando…

Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success

BACKGROUND: High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a prospective clinical study. METHODS: From January 2007 to June 2008, 110...

Descripción completa

Detalles Bibliográficos
Autores principales: Schopka, Simon, Schmid, Christof, Keyser, Andreas, Kortner, Ariane, Tafelmeier, Julia, Diez, Claudius, Rupprecht, Leopold, Hilker, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878302/
https://www.ncbi.nlm.nih.gov/pubmed/20444285
http://dx.doi.org/10.1186/1749-8090-5-34
_version_ 1782181849782550528
author Schopka, Simon
Schmid, Christof
Keyser, Andreas
Kortner, Ariane
Tafelmeier, Julia
Diez, Claudius
Rupprecht, Leopold
Hilker, Michael
author_facet Schopka, Simon
Schmid, Christof
Keyser, Andreas
Kortner, Ariane
Tafelmeier, Julia
Diez, Claudius
Rupprecht, Leopold
Hilker, Michael
author_sort Schopka, Simon
collection PubMed
description BACKGROUND: High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a prospective clinical study. METHODS: From January 2007 to June 2008, 110 patients with AF and concomitant open heart surgery were enrolled into the study. Main underlying heart diseases were aortic valve disease (50%), ischemic heart disease (48%), and mitral valve disease (18%). AF was paroxysmal in 29%, persistent in 31%, and long standing persistent in 40% of patients, lasting for 1 to 240 months (mean 24 months). Mean left atrial diameter was 50 ± 7 mm. Each patient underwent left atrial ablation with the Epicor system prior to open heart surgery. After surgery, the patients were treated with amiodarone and coumadin for 6 months. Follow-up studies including resting ECG, 24 h Holter ECG, and echocardiography were obtained at 6 and 12 months. RESULTS: All patients had successful application of the system on the beating heart prior to initiation of extracorporeal circulation. On average, 11 ± 1 ultrasound transducer elements were used to create the box lesion. The hand-held probe for additional linear lesions was employed in 83 cases. No device-related deaths occurred. Postoperative pacemaker insertion was necessary in 4 patients. At 6 months, 62% of patients presented with sinus rhythm. No significant changes were noted at 12 months. Type of AF and a left atrial diameter > 50 mm were predictors for failure of AF ablation. CONCLUSION: AF ablation with the Epicor system as a concomitant procedure during open heart surgery is safe and acceptably effective. Our overall conversion rate was lower than in previously published reports, which may be related to the lower proportion of isolated mitral valve disease in our study population. Left atrial size may be useful to determine patients who are most likely to benefit from the procedure.
format Text
id pubmed-2878302
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28783022010-05-29 Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success Schopka, Simon Schmid, Christof Keyser, Andreas Kortner, Ariane Tafelmeier, Julia Diez, Claudius Rupprecht, Leopold Hilker, Michael J Cardiothorac Surg Research article BACKGROUND: High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a prospective clinical study. METHODS: From January 2007 to June 2008, 110 patients with AF and concomitant open heart surgery were enrolled into the study. Main underlying heart diseases were aortic valve disease (50%), ischemic heart disease (48%), and mitral valve disease (18%). AF was paroxysmal in 29%, persistent in 31%, and long standing persistent in 40% of patients, lasting for 1 to 240 months (mean 24 months). Mean left atrial diameter was 50 ± 7 mm. Each patient underwent left atrial ablation with the Epicor system prior to open heart surgery. After surgery, the patients were treated with amiodarone and coumadin for 6 months. Follow-up studies including resting ECG, 24 h Holter ECG, and echocardiography were obtained at 6 and 12 months. RESULTS: All patients had successful application of the system on the beating heart prior to initiation of extracorporeal circulation. On average, 11 ± 1 ultrasound transducer elements were used to create the box lesion. The hand-held probe for additional linear lesions was employed in 83 cases. No device-related deaths occurred. Postoperative pacemaker insertion was necessary in 4 patients. At 6 months, 62% of patients presented with sinus rhythm. No significant changes were noted at 12 months. Type of AF and a left atrial diameter > 50 mm were predictors for failure of AF ablation. CONCLUSION: AF ablation with the Epicor system as a concomitant procedure during open heart surgery is safe and acceptably effective. Our overall conversion rate was lower than in previously published reports, which may be related to the lower proportion of isolated mitral valve disease in our study population. Left atrial size may be useful to determine patients who are most likely to benefit from the procedure. BioMed Central 2010-05-05 /pmc/articles/PMC2878302/ /pubmed/20444285 http://dx.doi.org/10.1186/1749-8090-5-34 Text en Copyright ©2010 Schopka et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Schopka, Simon
Schmid, Christof
Keyser, Andreas
Kortner, Ariane
Tafelmeier, Julia
Diez, Claudius
Rupprecht, Leopold
Hilker, Michael
Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title_full Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title_fullStr Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title_full_unstemmed Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title_short Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
title_sort ablation of atrial fibrillation with the epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878302/
https://www.ncbi.nlm.nih.gov/pubmed/20444285
http://dx.doi.org/10.1186/1749-8090-5-34
work_keys_str_mv AT schopkasimon ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT schmidchristof ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT keyserandreas ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT kortnerariane ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT tafelmeierjulia ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT diezclaudius ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT rupprechtleopold ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess
AT hilkermichael ablationofatrialfibrillationwiththeepicorsystemaprospectiveobservationaltrialtoevaluatesafetyandefficacyandpredictorsofsuccess